These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37553406)

  • 21. SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses.
    Mandolesi M; Sheward DJ; Hanke L; Ma J; Pushparaj P; Perez Vidakovics L; Kim C; Àdori M; Lenart K; Loré K; Castro Dopico X; Coquet JM; McInerney GM; Karlsson Hedestam GB; Murrell B
    Cell Rep Med; 2021 Apr; 2(4):100252. PubMed ID: 33842900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exosome-Based Multivalent Vaccine: Achieving Potent Immunization, Broadened Reactivity, and Strong T-Cell Responses with Nanograms of Proteins.
    Cacciottolo M; Nice JB; Li Y; LeClaire MJ; Twaddle R; Mora CL; Adachi SY; Chin ER; Young M; Angeles J; Elliott K; Sun M
    Microbiol Spectr; 2023 Jun; 11(3):e0050323. PubMed ID: 37093009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines.
    Hoffmann MAG; Yang Z; Huey-Tubman KE; Cohen AA; Gnanapragasam PNP; Nakatomi LM; Storm KN; Moon WJ; Lin PJC; West AP; Bjorkman PJ
    Cell; 2023 May; 186(11):2380-2391.e9. PubMed ID: 37146611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients.
    Tolan NV; Sherman AC; Zhou G; Nabel KG; Desjardins M; Melanson S; Kanjilal S; Moheed S; Kupelian J; Kaufman RM; Ryan ET; LaRocque RC; Branda JA; Dighe AS; Abraham J; Baden LR; Charles RC; Turbett SE
    Microbiol Spectr; 2022 Apr; 10(2):e0021122. PubMed ID: 35311584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broad and Durable Humoral Responses Following Single Hydrogel Immunization of SARS-CoV-2 Subunit Vaccine.
    Ou BS; Saouaf OM; Yan J; Bruun TUJ; Baillet J; Zhou X; King NP; Appel EA
    Adv Healthc Mater; 2023 Nov; 12(28):e2301495. PubMed ID: 37278391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2.
    Gale EC; Powell AE; Roth GA; Meany EL; Yan J; Ou BS; Grosskopf AK; Adamska J; Picece VCTM; d'Aquino AI; Pulendran B; Kim PS; Appel EA
    Adv Mater; 2021 Dec; 33(51):e2104362. PubMed ID: 34651342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.
    Zedan HT; Smatti MK; Al-Sadeq DW; Al Khatib HA; Nicolai E; Pieri M; Bernardini S; Hssain AA; Taleb S; Qotba H; Issa K; Abu Raddad LJ; Althani AA; Nasrallah GK; Yassine HM
    J Med Virol; 2024 Mar; 96(3):e29527. PubMed ID: 38511514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.
    Ma X; Zou F; Yu F; Li R; Yuan Y; Zhang Y; Zhang X; Deng J; Chen T; Song Z; Qiao Y; Zhan Y; Liu J; Zhang J; Zhang X; Peng Z; Li Y; Lin Y; Liang L; Wang G; Chen Y; Chen Q; Pan T; He X; Zhang H
    Immunity; 2020 Dec; 53(6):1315-1330.e9. PubMed ID: 33275896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques.
    Garrido C; Curtis AD; Dennis M; Pathak SH; Gao H; Montefiori D; Tomai M; Fox CB; Kozlowski PA; Scobey T; Munt JE; Mallory ML; Saha PT; Hudgens MG; Lindesmith LC; Baric RS; Abiona OM; Graham B; Corbett KS; Edwards D; Carfi A; Fouda G; Van Rompay KKA; De Paris K; Permar SR
    Sci Immunol; 2021 Jun; 6(60):. PubMed ID: 34131024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.
    Joyce MG; Chen WH; Sankhala RS; Hajduczki A; Thomas PV; Choe M; Martinez EJ; Chang WC; Peterson CE; Morrison EB; Smith C; Chen RE; Ahmed A; Wieczorek L; Anderson A; Case JB; Li Y; Oertel T; Rosado L; Ganesh A; Whalen C; Carmen JM; Mendez-Rivera L; Karch CP; Gohain N; Villar Z; McCurdy D; Beck Z; Kim J; Shrivastava S; Jobe O; Dussupt V; Molnar S; Tran U; Kannadka CB; Soman S; Kuklis C; Zemil M; Khanh H; Wu W; Cole MA; Duso DK; Kummer LW; Lang TJ; Muncil SE; Currier JR; Krebs SJ; Polonis VR; Rajan S; McTamney PM; Esser MT; Reiley WW; Rolland M; de Val N; Diamond MS; Gromowski GD; Matyas GR; Rao M; Michael NL; Modjarrad K
    Cell Rep; 2021 Dec; 37(12):110143. PubMed ID: 34919799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera.
    Seephetdee C; Bhukhai K; Buasri N; Leelukkanaveera P; Lerdwattanasombat P; Manopwisedjaroen S; Phueakphud N; Kuhaudomlarp S; Olmedillas E; Saphire EO; Thitithanyanont A; Hongeng S; Wongtrakoongate P
    Antiviral Res; 2022 Aug; 204():105370. PubMed ID: 35772601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice.
    Wørzner K; Sheward DJ; Schmidt ST; Hanke L; Zimmermann J; McInerney G; Karlsson Hedestam GB; Murrell B; Christensen D; Pedersen GK
    EBioMedicine; 2021 Jan; 63():103197. PubMed ID: 33422991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 vaccines based on viral nanoparticles displaying a conserved B-cell epitope show potent immunogenicity and a long-lasting antibody response.
    Affonso de Oliveira JF; Zhao Z; Xiang Y; Shin MD; Villaseñor KE; Deng X; Shukla S; Chen S; Steinmetz NF
    Front Microbiol; 2023; 14():1117494. PubMed ID: 37152732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike.
    Zhang Y; Lu M; Mahesh KC; Kim E; Shamseldin MM; Ye C; Dravid P; Chamblee M; Park JG; Hall JM; Trivedi S; Chaiwatpongsakorn S; Kenny AD; Murthy SS; Sharma H; Liang X; Yount JS; Kapoor A; Martinez-Sobrido L; Dubey P; Boyaka PN; Peeples ME; Li J
    Proc Natl Acad Sci U S A; 2022 Aug; 119(33):e2201616119. PubMed ID: 35895717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
    Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
    Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
    mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
    Ji Y; Sui X; Miao W; Wang C; Wang Q; Duan Z; Wei B; Wu D; Wei M; Shao J; Zheng X; Zhu T
    Vaccine; 2024 Feb; 42(6):1292-1299. PubMed ID: 38296705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.
    Gu M; Torres JL; Li Y; Van Ry A; Greenhouse J; Wallace S; Chiang CI; Pessaint L; Jackson AM; Porto M; Kar S; Li Y; Ward AB; Wang Y
    Emerg Microbes Infect; 2021 Dec; 10(1):2016-2029. PubMed ID: 34651563
    [No Abstract]   [Full Text] [Related]  

  • 40. A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern.
    Lee IJ; Lan YH; Wu PY; Wu YW; Chen YH; Tseng SC; Kuo TJ; Sun CP; Jan JT; Ma HH; Liao CC; Liang JJ; Ko HY; Chang CS; Liu WC; Ko YA; Chen YH; Sie ZL; Tsung SI; Lin YL; Wang IH; Tao MH
    Emerg Microbes Infect; 2023 Dec; 12(1):2149353. PubMed ID: 36395071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.